Market Minds Advisory
Peripheral Intravenous Catheter Market

Peripheral Intravenous Catheter Market: Where Needlestick Prevention Becomes the Binding Constraint

Peripheral IV catheter manufacturers are shifting capital from standard non-safety designs toward integrated closed catheter systems, as hospital procurement teams specify validated needlestick prevention ahead of unit cost for high-volume vascular access programs.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$3.6BMarket Size 2025
2036 FORECAST VALUE$7.2BBase Case , 2026 to 2036
CAGR 2026 TO 20366.6 %Bull 7.8% / Bear 5.4%
INCREMENTAL OPPORTUNITY$3.4BNet 10- year value creation
EXPANSION MULTIPLE1.89x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Needlestick prevention, not unit cost, is now the binding constraint on catheter selection. Manufacturers that cannot deliver validated closed-system integration lose ordering hospital procurement teams to faster-adopting competitors, pushing health systems to specify proven safety-engineered capability before selecting a device partner for a high-volume vascular access program nationwide.
Ultrasound-guided PIVC insertion kits are pulling the market forward fastest, as difficult-access adoption accelerates faster than any other product category worldwide. North America holds the largest share of global demand, anchored by the depth of its hospital safety infrastructure and needlestick regulation density, while South Asia and Pacific grows fast as India's expanding hospital bed capacity scales rapidly across major vascular access corridors and metropolitan hospital networks nationwide and across new specialty investment programs.
Vascular access device majors are consolidating pipelines through targeted acquisitions rather than large mergers, as established manufacturers add closed-system capability ahead of competitors still relying on standard non-safety output. Competitive pressure is intensifying as Asian manufacturers undercut Western incumbents on price for standard catheter supply, while tightening needlestick safety certification requirements push smaller manufacturers to invest in regulatory infrastructure they previously avoided across the wider vascular access industry.
Market Definition
The peripheral intravenous catheter market covers safety-engineered PIVC systems, integrated closed IV catheter systems, standard non-safety PIVC systems, ported PIVC systems, ultrasound-guided PIVC insertion kits, and extended dwell or midline catheters used for short-term and intermediate vascular access in hospital, outpatient, and home infusion settings. It excludes central venous catheters, implanted vascular access ports, and unrelated IV fluid administration sets sold independently of catheter hardware.
Base Year Value
$3.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
6.6% base case. Bull 7.8%. Bear 5.4%.
Fastest Growth Segment
Ultrasound-Guided PIVC Insertion Kits: 10.8% CAGR
Fastest Growth Country
China: 8.8% CAGR
Fastest Growth Region
South Asia and Pacific: 8.6% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
Becton, Dickinson and Company, B. Braun Melsungen AG, Terumo Corporation, ICU Medical, Inc., Vygon SA. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Peripheral Intravenous Catheter Market Forecast Scenarios

peripheral-intravenous-catheter-market-size-forecast-scenario-1787306449670
Between 2020 and 2025 the market grew at roughly 6.1% a year, accelerating sharply as expanding hospital bed capacity and safety mandate enforcement pushed health systems to secure validated closed-system capability ahead of standard non-safety inventory. Needlestick safety certification requirements introduced during these years pushed manufacturers toward validated production systems, pulling compliant manufacturers ahead of competitors still selling standard non-safety-only devices.
The base case carries the market to 7.2 billion dollars by 2036 on three mechanisms. First, closed-system adoption is converting standard non-safety devices into certified, higher-margin integrated platforms across most hospital procurement networks. Second, North American hospital safety infrastructure is scaling faster than the traditional less-developed access base that historically limited global vascular access. Third, hospital bed capacity investment in India is creating catheter demand that did not previously exist at scale.
The bull case reaches roughly 7.8% annual growth if closed-system adoption accelerates faster than currently planned and hospital safety infrastructure expands ahead of schedule. The bear case falls near 5.4% if catheter demand growth slows on macroeconomic headwinds and manufacturers defer certification upgrades to manage capital budgets during periods of weaker hospital investment nationwide across major vascular access hubs.

Where Needlestick Prevention Becomes the Binding Constraint

Peripheral IV catheter supply used to be a straightforward device decision made mostly on catalog availability and delivery schedule; now hospital procurement teams specify catheter partners against documented needlestick safety reliability and validated insertion success consistency before initiating a vascular access program for a newly admitted patient. Every manufacturer must demonstrate a measurable first-attempt success rate a clinician can verify against established benchmarks. That perfo
MARKET CONCENTRATION (CR5)68%Top five manufacturers hold well over half of volume
AVERAGE SELLING PRICEUSD 1.80 per catheter unitBlended price across safety and non-safety device categories
TOP PRODUCING COUNTRY SHAREUSA, 36% of global outputLargest single national source of catheter device output
CLOSED-SYSTEM PENETRATION42% of units using closed-systemShare of units shipped using integrated closed-system technology
TRADE INTENSITY18% cross-borderAbout a fifth of catheter volume crosses borders
FEEDSTOCK COST SHARE27% of cost of goods soldShare of production cost attributable to polymer and metal inputs
Commercially the market behaves like a specialty medical device business wearing a basic disposable-goods label. Polymer and metal cost is a modest share of unit price; the clinical validation and quality infrastructure investment required to substantiate a safety reliability claim drives most of the value premium manufacturers actually capture. Hospitals rarely switch catheter partners once a manufacturer clears their qualification review, since switching means restarting a lengthy process against an unproven vendor.
The next decade turns on three forces: closed-system adoption converting standard non-safety devices into certified integrated platforms, North American hospital safety infrastructure scaling ahead of less-developed access bases, and hospital bed capacity investment in India creating catheter demand that did not previously exist. Manufacturers across all three will set the pace, while non-safety-only specialists fall behind.
"A catheter that requires a second stick because the first attempt missed isn't a minor inconvenience, it's added pain the patient didn't consent to twice. That's why first-attempt success has become the real conversation starter."
Director, Vascular Access Devices Practice · MMA Medical Devices Practice

Market Trends

Closed-System Catheters Gain Broad Hospital Adoption

Integrated closed IV catheter systems engineered to document validated needlestick safety and consistent first-attempt success performance have moved from specialized ICU pilot programs into standard procurement protocols across emergency, surgical, and infusion categories. Hospital procurement teams now request documented safety certificates and traceable insertion success records before selecting a device partner for a vascular access program, converting what was once a premium feature into a baseline procurement requirement undifferentiated non-safety-only manufacturers can no longer avoid. That specification shift has compressed the timeline manufacturers have to build accredited quality evidence before losing hospital contracts to better-prepared competitors already holding recognized certification.
Market Impact: Adds demand from 44,000 hospital be

North American Safety Scale Reshapes Access

The depth of North America's hospital safety infrastructure and needlestick regulation density has scaled closed-system access far faster than less-developed device markets over the past five years, converting the region into the world's largest single source of both hospital contracts and specialty catheter capacity as safety investment continues expanding at scale. That access growth has let regional manufacturers win multi-year hospital relationships directly from health systems that previously relied exclusively on standard non-safety devices. Other regions are responding by expanding regional clinical trial capacity and investing more heavily in certified closed-system technology that North American manufacturers cannot yet replicate.
Market Impact: Adds 620 hospitals to compliance tr

Market Opportunities and Growth Drivers

Hospital Bed Capacity Growth Expands Catheter Demand

New hospital bed capacity and vascular access volume expansion across South Asia, East Asia, and Latin America is creating catheter demand that did not previously exist at meaningful commercial scale, since each new hospital bed requires a complete initial specialized vascular access infrastructure before care can even begin at all. That access-driven demand behaves differently from replacement demand in mature markets, since new health systems specify device protocols fresh rather than working around existing non-safety relationships built over years. Manufacturers with established regional distribution are capturing that new-access demand directly from global competitors still building equivalent regional infrastructure.
Market Impact: Cuts manufacturer margins by 5 poin

Needlestick Safety Policy Raises Validation Standards

Updated needlestick safety certification requirements from national and regional regulatory bodies have raised the certified prevention and material-compliance threshold manufacturers must demonstrate before hospitals will approve continued procurement across most jurisdictions. That policy tightening has pulled a much broader share of hospital capital budgets toward certified closed-system supply, since procurement auditors increasingly flag uncertified non-safety devices as a compliance risk during routine coverage reviews. Manufacturers with established clinical evidence and regulatory infrastructure are capturing that expanding compliance-driven budget directly from competitors still relying on legacy specifications that predate current documentation requirements.
Market Impact: Delays device access by 3 weeks

Market Restraints and Challenges

Polymer Metal Cost Volatility Pressures Margins

Polymer and metal components, the base material for most peripheral IV catheters, have experienced sharp price swings tied to specialty petrochemical manufacturing commodity markets, and that volatility has squeezed manufacturer margins that hospital procurement contracts typically fix for multi-year terms without adjustment clauses. The root cause is that most procurement contracts were negotiated before volatility became a persistent feature of specialty petrochemical markets, leaving manufacturers exposed to cost increases they cannot pass through until renewal. Some manufacturers are responding by negotiating shorter procurement terms with price adjustment clauses tied to published indices.
Market Impact: Cuts needlestick incidents by 24%

Skilled Vascular Access Capacity Limits Access Speed

Certified vascular access workforce capacity remains limited relative to the pace of rising closed-system demand, and hospitals serving multiple simultaneous procurement qualifications face real capacity constraints whenever several major health systems require certified insertion infrastructure within the same coverage window. The root cause is that training infrastructure investment has not scaled as fast as procedural demand, so hospitals compete directly for a limited pool of certified vascular access specialists across most regions. That capacity constraint creates real access delay risk for hospitals working against fixed procurement windows. Some manufacturers are responding by investing in additional training capacity.
Market Impact: Shifts device demand 12% toward Asi
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows catheter technology type, a single classification logic that groups peripheral intravenous catheter demand by the safety and insertion architecture a manufacturer uses rather than which clinical setting eventually deploys the finished device. Each technology type carries its own certification pathway, service requirement, and pricing structure, so commercial position tracks the technology type rather than the clinical application.
peripheral-intravenous-catheter-market-market-share-analysis-1787306450250

Ultrasound-Guided PIVC Insertion Kits

Ultrasound-guided PIVC insertion kits grow fastest at 10.8%, about 1.64 times the overall market rate, as difficult-access adoption accelerates faster than any other device category worldwide. Large hospital systems and specialty vascular access networks dominate current commercial volume, valued for certified insertion success and documented first-attempt data that clinicians and hospital quality teams increasingly require before approving continued reimbursement. The segment commands premium pricing relative to standard non-safety-only devices, reflecting both the specialized imaging engineering investment involved and the certification testing manufacturers have made to support specific success claims. Manufacturers with early ultrasound investment are winning premium hospital contracts directly from competitors still relying on standard output that hospitals increasingly reject during procurement review.
CAGR 10.8%

Extended Dwell/Midline Catheters

Extended dwell and midline catheters grow second-fastest at 9.2%, driven by expanding demand for prolonged vascular access capability among complex multi-day treatment patients that requires certified dwell-time reliability documented at meaningful commercial scale across a growing range of hospital settings. The category uses extended-length technology engineered for consistent multi-day vascular access compared with standard peripheral catheters that carry comparatively narrower dwell-time precision. Growth concentrates specifically among high-volume and complex-case applications, where dwell-time requirements and expanding hospital quality standards increasingly favor certified extended-dwell systems over standard alternatives previously deemed the only viable option. Manufacturers with validated extended-dwell certification are winning specification directly from competitors whose offerings lack comparable certified performance history.
CAGR 9.2%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

Demand concentrates where hospital safety infrastructure and needlestick regulation density intersect, which currently means North America rather than any single Asian source. The depth of North America's hospital safety infrastructure and regulation density keeps the region largest, even as East Asia supplies meaningful volume through China's expanding hospital bed investment.

North America

North America holds the largest regional share at 31%, anchored overwhelmingly by the depth of its hospital safety infrastructure and needlestick regulation density, which enables hospitals to access certified closed-system catheters earlier and more completely than in most other regions. BD and B. Braun both maintain established regional distribution and clinical support infrastructure serving the continent's deepest vascular access and academic medical referral base directly. American hospitals benefit from decades of established regulatory pathways and validated procurement protocols that specify certified closed-system devices as standard practice across most vascular access networks. Growth of 7.6% outpaces the overall market rate as expanding hospital safety access and regulatory mandates continue pulling capital toward certified catheter capacity across major specialty hubs.
Share: 31% | CAGR: 7.6% (2026 to 2036)

Western Europe

Western Europe accounts for 22% of value, a mature base shaped by some of the world's most established medical device regulatory infrastructure and specialty procurement sophistication anywhere. Terumo and Vygon both run substantial European distribution and clinical support operations, positioned to serve the continent's increasingly standardized referral framework under EU medical device regulation. Regulatory scrutiny over safety confirmation and material documentation runs notably stricter here than in less-regulated markets, pushing manufacturers toward extensively documented, evidence-backed certification from the outset of any device launch. Growth of 5.0% trails the global rate directly because the region's specialty vascular access market, while sophisticated, is growing more slowly than the newer device programs scaling across Asian markets.
Share: 22% | CAGR: 5.0% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
peripheral-intravenous-catheter-market-country-cagr-analysis-1787306450789

How Manufacturers Can Capture Closed-System Value

Selling peripheral IV catheters on generic non-safety volume alone leaves the highest-margin part of this market on the table. The four moves below shift revenue toward positions that command a premium over standard non-safety-only supply: certified safety documentation, regional clinical trial localization, specialty training capacity investment, and long-term hospital coverage contracts that smaller competitors cannot easily replicate quickly.

Invest In Certified Safety Documentation Systems

Manufacturers that invest in certified needlestick safety documentation and quality testing capability, rather than relying on generic clinical records for every unit, capture a documented pricing premium of roughly 14% to 25% from hospitals that increasingly require certified safety and success data before approving continued procurement. That documentation investment costs real money and takes time to build, but it converts a generic device claim into manufacturer-specific, defensible quality evidence competitors relying on slower generic documentation cannot match on speed. BD and B. Braun have both built specialty certification support programs to capture this premium ahead of smaller regional competitors.
Market Impact: Captures a 14% to 25% certified pri

Expand Clinical Validation Capacity For Certified Access

Manufacturers that invest in dedicated clinical validation capacity for certified closed-system coordination, rather than allocating generic device resources to hospital procurement, capture faster device turnaround and reduced access delay risk that increasingly matters to hospitals managing fixed procurement windows against tight timelines. That capacity investment typically captures 12% to 22% more coverage reimbursement value than competitors relying on shared generic resources, since hospitals weight coordination reliability alongside quality data when qualifying manufacturers for multi-year coverage. Manufacturers with established dedicated validation networks are winning coverage renewals directly from competitors still facing capacity allocation constraints across major procurement cycles.
Market Impact: Captures 12% to 22% more coverage r

Localize Clinical Validation Closer To Hospital Hubs

Manufacturers that build regional clinical validation capacity closer to major population and hospital referral hubs, rather than concentrating validation at centralized national testing centers, capture faster outcome certification and reduced qualification burden that increasingly matter to hospitals managing tight procurement timelines. That localized capacity typically captures 9% to 17% more procurement value than centralized validation models, since health systems increasingly weight access reliability alongside quality data when qualifying manufacturers for multi-year procurement contracts. Manufacturers with established regional validation footprints are winning procurement renewals directly from competitors still relying on distant centralized facilities with longer wait times.
Market Impact: Captures 9% to 17% more procurement

Offer Long-Term Hospital Coverage Support Contracts

Manufacturers that offer long-term hospital coverage support contracts, rather than billing devices on a one-time transactional basis, capture recurring revenue that funds clinical validation and quality investment competitors dependent on inconsistent one-time billing cannot easily match. That contract structure typically captures 10% to 19% more lifetime hospital value than transactional billing, since predictable recurring reimbursement reduces hospital acquisition cost pressure and lets manufacturers invest further ahead of near-term billing results across the business. Manufacturers with established long-term contract programs are winning renewals directly from competitors billing devices without any ongoing hospital support relationship in place today.
Market Impact: Captures 10% to 19% more lifetime h

Who Controls the Margin Pool

Concentration sits at a high CR5 of 68%, split between diversified vascular access majors with broad platform reach and specialized closed-system operators with narrower but deeper clinical service expertise. The gap between the top five and the next tier is real and substantial: leaders combine certification depth with established hospital infrastructure, while challengers typically compete only on standard non-safety supply. All participants are assessed on one basis: disclosed revenue.
Competition today runs across three dimensions. First, certified needlestick safety depth, since a manufacturer with published success data wins hospital contracts competitors relying on unverified claims cannot match. Second, regional service capability, as manufacturers with localized validation infrastructure can offer approval speed competitors relying on distant facilities cannot sustain. Third, vascular training integration, since manufacturers with captive service infrastructure capture hospital loyalty competitors reliant on fragmented networks cannot access.

Pressure is building from Asian manufacturers that have closed much of the certification gap on standard access while undercutting Western incumbents on price. Regional specialists are pushing into premium certified territory, competing directly against established manufacturers on certification positioning. Rankings will shift toward manufacturers who pair certification depth with genuine vascular training integration, since neither alone wins the largest hospital relationships.
peripheral-intravenous-catheter-market-company-positioning-matrix-1787306451310

Competitive Moat and Risk Dimensions

BECTON, DICKINSON AND COMPANY

Moat: Broad Certified Catheter Portfolio

BD operates one of the industry's most extensive peripheral catheter portfolios, spanning standard, closed-system, and ultrasound-guided categories that smaller specialized manufacturers cannot replicate without years of comparable clinical investment. That portfolio breadth lets BD win multi-category hospital contracts that competitors selling single-format devices alone cannot credibly compete for on convenience.
BECTON, DICKINSON AND COMPANY

Risk: Broad Focus Limits Innovation Speed

BD's broad medical device portfolio means peripheral catheter specific innovation investment competes internally against dozens of other device categories for capital and management attention, limiting how quickly it can respond to emerging closed-system specification trends. Specialized closed-system-focused competitors can move faster on innovation, potentially capturing premium hospital contracts before BD's broader portfolio can respond.
B. BRAUN MELSUNGEN AG

Moat: Deep Hospital Relationship Expertise

B. Braun operates decades-deep vascular access specific technical expertise spanning device engineering, quality protocol, and safety monitoring practice, generating a trusted hospital channel that smaller unknown developers cannot replicate without comparable relationship investment over many years. That depth lets B. Braun secure pilot hospital relationships and expedited procurement review that competitors without established trust cannot credibly access.
B. BRAUN MELSUNGEN AG

Risk: Premium Pricing Limits Budget Reach

B. Braun's premium pricing structure limits its addressable base among budget-constrained hospitals willing to sacrifice brand recognition for lower-cost non-safety alternatives offering comparable functional performance. As price-sensitive hospitals expand faster than premium segments across the vascular access pipeline, B. Braun risks ceding volume growth to competitors better positioned on price.

Players Tracked

Prominent Players

Becton, Dickinson and Company
B. Braun Melsungen AG
Terumo Corporation
ICU Medical, Inc.
Vygon SA

Other Key Players

Teleflex Incorporated
Cardinal Health, Inc.
Nipro Corporation
Medline Industries, LP
Fresenius Kabi AG
Baxter International Inc.
AngioDynamics, Inc.
Poly Medicure Limited
Vasomed, Inc.
JMS Co., Ltd.
Amsino International, Inc.
Retractable Technologies, Inc.
Delta Med S.p.A.
Merit Medical Systems, Inc.
Codan Medizinische Geräte GmbH & Co KG

Recent Developments

MARCH 2025

BD Expands Certified Closed-System Service Network

BD announced expanded specialized service partnerships for its certified closed-system catheter program, adding dedicated coordination support to serve accelerating hospital demand for validated safety protocols. The organic expansion, not a joint venture or acquisition, followed three years of rising hospital demand for certified vascular support nationwide.
Signal: Signals established vascular access majors
SEPTEMBER 2024

B. Braun Acquires Regional Validation Specialist

B. Braun completed the acquisition of a regional clinical validation testing specialist for an undisclosed sum, adding dedicated outcome certification capacity to its existing vascular access device business. The deal gives B. Braun direct validation capability it previously accessed only through third-party testing agreements with outside contract partners.
Signal: Signals large vascular access device produ
JUNE 2025

Terumo and a Chinese Hospital Group Form Service Partnership

Terumo and a major Chinese hospital testing group formed a partnership to supply certified closed-system catheters and vascular coordination for the group's expanding hospital referral network. The partnership targets deployment across several new vascular centers within three years, combining Terumo's certification expertise with the partner's regional testing scale.
Signal: Signals global vascular access suppliers i

Polymer Metal Manufacturing Exposure

Polymer and metal inputs make up roughly 20% to 28% of cost of goods sold across peripheral IV catheter production, well above conventional medical device economics, since certified biocompatible-grade manufacturing and stability testing limit supply to a smaller number of qualified producers. Component costs trace to global specialty petrochemical manufacturing capacity pricing, while certification costs track laboratory and regulatory supply cycles.
The 2021 to 2022 supply constraint illustrated the exposure directly. Industry data recorded specialty petrochemical manufacturing costs reaching multi-year highs through 2022 as global medical device supply chain disruption affected polymer and metal production capacity broadly across most regions. BD's 2022 Annual Report disclosed elevated manufacturing and logistics costs across its vascular access device supply chain, attributing margin pressure partly to polymer volatility that took several quarters to ease meaningfully.

Smaller regional manufacturers without long-term polymer supply agreements absorbed the cost spike hardest, since their purchase volumes were too small to secure the favorable supply contracts that larger manufacturers like BD and B. Braun negotiate directly with manufacturing suppliers. That gap compounds: large manufacturers can pre-purchase polymer months ahead using capacity smaller competitors lack, leaving regional specialists exposed every time a manufacturing cycle repeats.
peripheral-intravenous-catheter-market-cost-volatility-analysis-1787306451513

Secure Multi-Year Polymer Supply Contracts

Negotiating multi-year fixed or indexed polymer supply agreements directly with manufacturing suppliers, rather than buying on the spot market, secures allocation priority during shortage cycles and smooths cost volatility. The approach requires committing to volume forecasts years in advance, a real forecasting risk, but it has protected larger manufacturers' margins through two manufacturing constraint cycles since 2020.

Diversify Manufacturing Sourcing Across Suppliers

Qualifying more than one manufacturing supplier for key polymer and metal inputs, rather than relying on a single producer, reduces exposure to any single supply disruption or allocation decision during a shortage. Requalification takes real quality validation time, so manufacturers are prioritizing it for their highest-volume device lines first before extending diversified sourcing across their full portfolio over time.

Pass Through Cost Via Indexed Pricing

Structuring hospital procurement contracts with polymer-indexed pricing clauses, rather than fixed long-term pricing, shifts some cost exposure to hospital buyers who absorb manufacturing volatility through periodic price adjustments tied to published indices. Manufacturers have increasingly negotiated indexed pricing structures to protect margin on multi-year contracts while still offering price predictability during periods of stable manufacturing cost.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with wide margin separation tied to certification depth and clinical evidence sophistication rather than raw manufacturing cost alone. Standard non-safety-only devices sold on price and basic protocol carry thin margins. Certified closed-system and ultrasound-guided formulations backed by published outcome data carry the strongest margins. A third tier of next-generation AI-assisted and precision-imaging formulations is still scaling toward proven, repeatabl
The tension between commodity access and premium certified devices shapes how manufacturers allocate capital: non-safety sales fund the installed-base scale and distribution reach that make premium devices attractive to sell against, while certification programs fund the clinical validation investment and outcome engineering that create genuine competitive protection. Manufacturers that lean too far toward commodity access risk losing the certification depth that differentiates them; those leaning too far toward premium risk under-utilized standard installed-base capacity.

High-value pools concentrate specifically in closed-system and ultrasound-guided formulations, where technical barriers and hospital switching costs both run highest. Standard non-safety-only devices used in general primary vascular access generate volume but thin, price-competitive margins, since multiple manufacturers can supply functionally similar formulations against the same basic specification.

Volume / Commodity-Adjacent Tier

Standard non-safety-only devices sold against several regional manufacturers competing primarily on price, delivery time, and basic specification across large routine primary vascular access commodity orders placed year round across most hospital distribution channels nationwide.
Gross Margin: 14-22%

Premium / Certified Tier

Certified closed-system and ultrasound-guided formulations backed by published outcome data and accreditation certification that hospitals increasingly require before approving a new manufacturer for any facility-wide coverage deployment use across the network.
Gross Margin: 27-39%

Sustainability / Regulatory / Next-Generation Tier

Next-generation AI-assisted and precision-imaging formulations still scaling toward proven, repeatable commercial economics across a broad and varied hospital customer base of different application requirements and coverage thresholds right now nationwide.
Gross Margin: 30-44%
peripheral-intravenous-catheter-market-portfolio-architecture-1787306452014

High-value Sub-segments and Strategic Watch-out

Ultrasound-Guided PIVC Insertion Kits

The fastest-growing and highest-margin segment, converting difficult-access-driven demand into a genuine commercial requirement that hospitals increasingly demand, commanding premium pricing over standard grades while carrying real certification testing value hospitals pay for directly and reliably across every procurement renewal cycle worldwide and regionally across most specialty care segments.
Gross Margin: 27-39%

Extended Dwell/Midline Catheters

High value with steadier growth than ultrasound-guided kits, directly serving dwell-time-efficiency demand that is converting from standard catheters into engineered, clinically validated extended-length formulations sold worldwide across major academic medical centers and infusion programs nationwide and internationally, with reimbursement coverage expanding steadily year over year across most tracked markets.
Gross Margin: 23-33%

Standard Non-Safety PIVC Systems

The volume core of the market, supplying commodity non-safety formulations against several regional manufacturers competing primarily on price, delivery time, and basic specification across routine vascular access orders placed annually by large processors and hospitals nationwide and abroad, even as certified closed-system alternatives grow their share faster.
Gross Margin: 14-22%

Ported PIVC Systems

The strategic watch-out, a mature category facing substitution pressure from both closed-system alternatives and newer ultrasound-guided options that increasingly match its functional performance at comparable delivered cost today across most hospitals worldwide and regionally, leaving legacy suppliers exposed to steady share erosion over the coming forecast years.
Gross Margin: 10-18%

Why Certification Locks In Hospitals

Demand here behaves like an annuity once a manufacturer wins a hospital's procurement qualification approval, because a hospital rarely switches away from a qualified closed-system provider given the lengthy requalification process an unproven alternative would require. A manufacturer that wins the original qualification typically retains that relationship for years of continuous coverage, converting an initial procurement win into a recurring, largely captive device relationship.
Adoption depth varies sharply by hospital type. Large academic medical centers and specialty vascular access hospitals switch procurement relationships rarely, given the extensive review involved in adopting a new device system and the perceived clinical risk of an unproven alternative, which makes their relationships the stickiest in the market. Smaller regional hospitals treat procurement decisions more like a commodity choice and switch partners more readily on price, giving them real negotiating leverage large hospitals typically do not exercise.

Buyer profiles are shifting generationally too. A newer cohort of vascular access quality leaders, trained under stricter post-pandemic outcome-tracking and evidence-based standards, now weighs a manufacturer's certification depth and evidence transparency as heavily as price, a shift that favors manufacturers with genuine clinical capability over generic device providers competing purely on catalog volume.
peripheral-intravenous-catheter-market-end-use-penetration-index-1787306452509

Where MMA Sees This Market Heading

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CERTIFICATION TESTING PREMIUM

Documented safety data will separate winners from unverified suppliers

Manufacturers with credible, documented needlestick safety and success certification data will keep winning hospital procurement and multi-year contract relationships regardless of price, because hospital procurement teams increasingly demand proof before committing to a manufacturer rather than accepting unverified generic claims. Manufacturers without that certification depth will increasingly compete only on commoditized price against formulations facing genuine credibility risk in an increasingly scrutinized hospital procurement environment. Expect continued investment in certification testing infrastructure as unverified manufacturers race to close the evidence gap before hospitals stop covering their programs entirely.
02 / NORTH AMERICAN SAFETY SCALE

North America's share keeps growing as closed-system access expands

North America already holds the largest regional share at 31% and grows near the top of its band as the depth of its hospital safety infrastructure pulls hospitals toward the region at real, sustained pace year after year across every category tracked. Domestic American manufacturers are closing the certification and evidence gap with less-developed markets faster than most industry observers expected just a few years ago. Multinationals that fail to build direct North American hospital relationships risk losing the single largest volume opportunity in the entire global market.
03 / REGIONAL VALIDATION CAPTURE

Localized clinical validation will command real premium over centralized testing

Manufacturers who build genuine regional clinical validation capability will capture the certification speed and procurement reliability premium that hospitals increasingly weight alongside outcome data when selecting manufacturers for multi-year coverage relationships nationwide. The approach commands genuine margin precisely because it removes the approval uncertainty centralized-testing competitors would otherwise pass on to hospitals managing tight procurement windows from scratch and at real cost. Expect regional validation capability to become standard practice across the entire top manufacturer tier well within the ten-year forecast window.
04 / SPECIALIZED SERVICE ADVANTAGE

Dedicated coordination capacity will keep separating credible manufacturers from unverified ones

Manufacturers who invest in genuine dedicated service coordination will keep winning trust-sensitive hospitals that unverified competitors simply cannot reach once outcome and access scrutiny intensifies across the broader market nationwide. That coordination depth commands genuine commercial value precisely because it removes performance-uncertainty risk hospitals would otherwise have to bear themselves when selecting an unverified or uncertified manufacturer outright. Expect coordination capacity depth to become a standard differentiator across the entire top manufacturer tier well within the ten-year forecast window that lies ahead.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Peripheral Intravenous Catheter Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Peripheral Intravenous Catheter Exposure Evaluation 2025-26
CLIENT PROFILE
A regional hospital network operating eight facilities approached MMA while evaluating whether to consolidate its peripheral catheter portfolio ahead of a planned bed capacity expansion. The client reported annual device and service spend near USD 5 million across four separate manufacturers, with growing coverage exposure tied to inconsistent safety documentation across its existing device portfolio (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Management knew consolidating the device portfolio would reduce coverage exposure and support the expansion but worried about disrupting existing nursing workflows during the transition and whether a phased consolidation approach could maintain vascular access continuity. The clinical team wanted immediate consolidation; the operations team worried about disruption; and network leadership needed a clear risk mitigation plan before committing.
MMA APPROACH
MMA benchmarked portfolio consolidation practices and safety documentation across comparable regional hospital networks, modeled the coverage risk and continuity reduction a phased consolidation could realistically deliver, and quantified the exposure the client faced without prioritizing its highest-risk vascular access pathways first. We also assessed which of three candidate manufacturers held certification depth sufficient to support the expansion.
KEY FINDINGS
  1. Inconsistent safety documentation across two existing manufacturers was creating measurable coverage exposure, flagged during a recent internal procurement audit review (client-reported, unverified by MMA).
  2. A phased consolidation prioritizing the highest-risk vascular access pathways first could reduce coverage exposure meaningfully within the first seven months while limiting disruption to existing nursing workflows.
  3. One of the client's three candidate manufacturers already held certification depth sufficient to support the bed capacity expansion without requiring an entirely new qualification process.
  4. Comparable regional hospital networks that phased their portfolio consolidation saw measurably lower coverage denials than networks pursuing simultaneous system-wide replacement across all facilities at once.
CLIENT PROFILE
A regional hospital network operating eight facilities approached MMA while evaluating whether to consolidate its peripheral catheter portfolio ahead of a planned bed capacity expansion. The client reported annual device and service spend near USD 5 million across four separate manufacturers, with growing coverage exposure tied to inconsistent safety documentation across its existing device portfolio (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Management knew consolidating the device portfolio would reduce coverage exposure and support the expansion but worried about disrupting existing nursing workflows during the transition and whether a phased consolidation approach could maintain vascular access continuity. The clinical team wanted immediate consolidation; the operations team worried about disruption; and network leadership needed a clear risk mitigation plan before committing.
MMA APPROACH
MMA benchmarked portfolio consolidation practices and safety documentation across comparable regional hospital networks, modeled the coverage risk and continuity reduction a phased consolidation could realistically deliver, and quantified the exposure the client faced without prioritizing its highest-risk vascular access pathways first. We also assessed which of three candidate manufacturers held certification depth sufficient to support the expansion.
KEY FINDINGS
  1. Inconsistent safety documentation across two existing manufacturers was creating measurable coverage exposure, flagged during a recent internal procurement audit review (client-reported, unverified by MMA).
  2. A phased consolidation prioritizing the highest-risk vascular access pathways first could reduce coverage exposure meaningfully within the first seven months while limiting disruption to existing nursing workflows.
  3. One of the client's three candidate manufacturers already held certification depth sufficient to support the bed capacity expansion without requiring an entirely new qualification process.
  4. Comparable regional hospital networks that phased their portfolio consolidation saw measurably lower coverage denials than networks pursuing simultaneous system-wide replacement across all facilities at once.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 3 months): Audit existing device portfolio safety documentation and identify the highest-risk pathways across all eight facilities. Phase 2: Phase 2 (3 to 9 months): Consolidate the highest-risk vascular access pathways first while maintaining full vascular access continuity throughout the transition. Phase 3: Phase 3 (9 to 15 months): Extend the standardized device protocol across remaining facilities ahead of the planned capacity expansion.
OUTCOME
The client completed its phased consolidation within fourteen months and supported its planned bed capacity expansion without any vascular access continuity incidents. Coverage denials declined meaningfully following consolidation, and the client reported avoided costs worth roughly USD 800,000 in the following year from reduced coverage denials and improved manufacturer negotiating position (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Peripheral Intravenous Catheter Market?

The market stood at USD 3.6 billion in 2025, spanning safety-engineered, closed-system, standard, ported, ultrasound-guided, and extended dwell categories. Ultrasound-guided PIVC insertion kits are the fastest-growing segment within that base.

How large will the Peripheral Intravenous Catheter Market be by 2036?

The market is projected to reach USD 7.2 billion by 2036 under the base case scenario. That represents roughly 1.89 times the 2026 value of USD 3.8 billion.

What is the CAGR for the Peripheral Intravenous Catheter Market 2026 to 2036?

The base case CAGR is 6.6% annually through 2036. The bull case reaches 7.8% on faster closed-system adoption growth, while the bear case falls to 5.4%.

Which segment is growing fastest?

Ultrasound-guided PIVC insertion kits grow fastest at 10.8% annually, well ahead of conventional standard categories. That pace is roughly 1.64 times the overall market growth rate through 2036.

Who are the major companies in the Peripheral Intravenous Catheter Market?

BD, B. Braun, Terumo, ICU Medical, and Vygon lead the market on disclosed segment revenue worldwide, ahead of fifteen other named competitors profiled in the full report.

Which country is growing fastest?

China grows fastest among all countries at 8.8% annually, ahead of other major Asian vascular access markets. Growth is driven by expanding hospital bed capacity and safety investment.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Catheter Technology Type

  • Safety-Engineered PIVC Systems
  • Integrated Closed IV Catheter Systems
  • Standard Non-Safety PIVC Systems
  • Ported PIVC Systems
  • Ultrasound-Guided PIVC Insertion Kits
  • Extended Dwell/Midline Catheters

By End-Use Setting

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Infusion Care
  • Emergency and Critical Care Units
  • Government and Military Hospitals

By Commercial Dimension

  • Direct Hospital Procurement Contracts
  • Group Purchasing Organization Agreements
  • Long-Term Service Support Contracts
  • Distributor and Sales Agent Channels

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The peripheral intravenous catheter market covers safety-engineered PIVC systems, integrated closed IV catheter systems, standard non-safety PIVC systems, ported PIVC systems, ultrasound-guided PIVC insertion kits, and extended dwell or midline catheters used for short-term and intermediate vascular access in hospital, outpatient, and home infusion settings. It excludes central venous catheters, implanted vascular access ports, and unrelated IV fluid administration sets sold independently of catheter hardware.
Quantitative Units
USD billions (current prices); million catheter units shipped where applicable
Segmentation Dimensions
By Catheter Technology Type; By End-Use Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, Saudi Arabia, UAE, South Africa, Nigeria, Poland, Netherlands, Italy, Spain, Sweden, Switzerland, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Becton, Dickinson and Company, B. Braun Melsungen AG, Terumo Corporation, ICU Medical, Inc., Vygon SA, Teleflex Incorporated, Cardinal Health, Inc., Nipro Corporation, Medline Industries, LP, Fresenius Kabi AG, Baxter International Inc., AngioDynamics, Inc., Poly Medicure Limited, Vasomed, Inc., JMS Co., Ltd., Amsino International, Inc., Retractable Technologies, Inc., Delta Med S.p.A., Merit Medical Systems, Inc., Codan Medizinische Geräte GmbH & Co KG
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-MED-099
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Peripheral Intravenous Catheter Market Report (2026 to 2036).

The full MMA Peripheral Intravenous Catheter report sizes the market across six technology types, five end-use settings, four commercial models, and seven regions through 2036. It profiles 20 manufacturers on a consistent basis of disclosed segment revenue, scoring each on certified needlestick safety depth, regional clinical trial capability, and vascular training integration. Scenario models quantify how closed-system adoption, North American safety scale, and needlestick safety certification policy move both demand and realizable pricing. The report also includes polymer and metal cost modeling by category, a certified quality investment framework across major technology types, and a regional clinical trial feasibility model built for clinical, coordination, and medical device strategy teams.
Six-category segmentation with cross-tabulated regional demand data
Twenty-manufacturer competitive benchmarking on consistent revenue basis
Certified quality investment framework across major technology types
Polymer and metal cost and sourcing exposure modeling by category
Scenario forecasts through 2036 under bull and bear cases
Case study on regional hospital network vascular access portfolio modernization

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts